[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

CA2185644A1 - Use of green porphyrins in ocular diagnosis and therapy - Google Patents

Use of green porphyrins in ocular diagnosis and therapy

Info

Publication number
CA2185644A1
CA2185644A1 CA002185644A CA2185644A CA2185644A1 CA 2185644 A1 CA2185644 A1 CA 2185644A1 CA 002185644 A CA002185644 A CA 002185644A CA 2185644 A CA2185644 A CA 2185644A CA 2185644 A1 CA2185644 A1 CA 2185644A1
Authority
CA
Canada
Prior art keywords
green porphyrin
bpd
neovasculature
green
porphyrin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002185644A
Other languages
French (fr)
Other versions
CA2185644C (en
Inventor
Joan W. Miller
Evangelos S. Gragoudas
Julia Levy
Tayyaba Hasan
Ursula Schmidt-Erfurth
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
VALEANT PHARMACEUTICALS INTERNATIONAL Inc
General Hospital Corp
Massachusetts Eye and Ear
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to CA002536069A priority Critical patent/CA2536069C/en
Publication of CA2185644A1 publication Critical patent/CA2185644A1/en
Application granted granted Critical
Publication of CA2185644C publication Critical patent/CA2185644C/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A61K49/0036—Porphyrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/409—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having four such rings, e.g. porphine derivatives, bilirubin, biliverdine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
    • A61K41/0071—PDT with porphyrins having exactly 20 ring atoms, i.e. based on the non-expanded tetrapyrrolic ring system, e.g. bacteriochlorin, chlorin-e6, or phthalocyanines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Photodynamic therapy of conditions of the eye characterized by unwanted neovasculature, such as macular degeneration, is effective using green porphyrins as photoactive agents. Green porphyrins are also effective in photodynamic therapy of pigmented tumors of the eye.
In addition, green porphyrins serve as effective dyes in ocular angiography.

Claims (26)

1. A method to treat conditions of the eye characterized by unwanted neovasculature, which method comprises:
a. administering to a subject in need of such treatment an amount of a green porphyrin sufficient to permit an effective amount to localize in said neovasculature;
b. permitting sufficient time to elapse to allow an effective amount of said green porphyrin to localize in said neovasculature; and c. irradiating neovasculature with light absorbed by the green porphyrin.
2. The method of claim 1 wherein the neovasculature is choroidal neovasculature.
3. The method of claim 1 wherein the green porphyrin is of formula (3) or (4).
4. The method of claim 3 wherein the green porphyrin is a BPD.
5. The method of claim 4 wherein the BPD is BPD-MA.
6. The method of claim 1 wherein said green porphyrin is complexed with low-density lipoprotein.
7. The method of claim 1 wherein said green porphyrin is contained in a liposomal preparation.
8. The method of claim 1 wherein said green porphyrin is coupled to a ligand which binds specifically a surface component of the neovasculature.
9. The method of claim 8 wherein said ligand comprises an antibody or an immunologically reactive fragment thereof.
10. A method to treat pigmented tumors in the eye, which method comprises:
a. administering to a subject in need of such treatment an amount of a green porphyrin sufficient to permit an effective amount to localize in said neovasculature;
b. permitting sufficient time to elapse to allow an effective amount of said green porphyrin to localize in said tumor; and c. irradiating tumor with light absorbed by the green porphyrin.
11. The method of claim 9 wherein the tumor is choroidal tumor.
12. The method of claim 10 wherein said green porphyrin is of formula (3) or (4).
13. The method of claim 12 wherein said green porphyrin is a BPD.
14. The method of claim 13 wherein said BPD is BPD-MA.
15. The method of claim 10 wherein said green porphyrin is complexed with low-density lipoprotein.
16. The method of claim 10 wherein said green porphyrin is contained in a liposomal preparation.
17. The method of claim 10 wherein said green porphyrin is coupled to a ligand which binds specifically a surface component of the tumor.
18. The method of claim 17 wherein said ligand comprises an antibody or an immunologically reactive fragment thereof.
19. A method to observe the condition of blood vessels in the eye, which method comprises:
a. administering to a subject comprising at least one eye for which said observation is desired an amount of green porphyrin which will provide an observable amount of green porphyrin in the blood vessels of said eye;
b. permitting sufficient time to elapse so that an observable amount of said green porphyrin resides in the blood vessels of the eye; and c. observing the blood vessels in which said green porphyrin resides.
20. The method of claim 19 wherein said green porphyrin is of formula (3) or (4).
21. The method of claim 20 wherein said green porphyrin is a BPD.
22. The method of claim 21 wherein said BPD is BPD-MA.
23. The method of claim 19 wherein said green porphyrin is complexed with low-density lipoprotein.
24. The method of claim 19 wherein said green porphyrin is contained in a liposomal preparation.
25. The method of claim 19 wherein said green porphyrin is coupled to a ligand which binds specifically a surface component of the tumor.
26. The method of claim 25 wherein said ligand comprises an antibody or an immunologically reactive fragment thereof.
CA2185644A 1994-03-14 1994-03-14 Use of green porphyrins in ocular diagnosis and therapy Expired - Lifetime CA2185644C (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CA002536069A CA2536069C (en) 1994-03-14 1994-03-14 Use of green porphyrins in ocular diagnosis and therapy

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US1994/002639 WO1995024930A1 (en) 1994-03-14 1994-03-14 Use of green porphyrins in ocular diagnosis and therapy

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CA002536069A Division CA2536069C (en) 1994-03-14 1994-03-14 Use of green porphyrins in ocular diagnosis and therapy

Publications (2)

Publication Number Publication Date
CA2185644A1 true CA2185644A1 (en) 1995-09-21
CA2185644C CA2185644C (en) 2011-04-12

Family

ID=22242340

Family Applications (2)

Application Number Title Priority Date Filing Date
CA2185644A Expired - Lifetime CA2185644C (en) 1994-03-14 1994-03-14 Use of green porphyrins in ocular diagnosis and therapy
CA002536069A Expired - Lifetime CA2536069C (en) 1994-03-14 1994-03-14 Use of green porphyrins in ocular diagnosis and therapy

Family Applications After (1)

Application Number Title Priority Date Filing Date
CA002536069A Expired - Lifetime CA2536069C (en) 1994-03-14 1994-03-14 Use of green porphyrins in ocular diagnosis and therapy

Country Status (3)

Country Link
AU (1) AU6813694A (en)
CA (2) CA2185644C (en)
WO (1) WO1995024930A1 (en)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5770592A (en) * 1991-11-22 1998-06-23 Alcon Laboratories, Inc. Prevention and treatment of ocular neovascularization using angiostatic steroids
JP3845469B2 (en) 1996-02-21 2006-11-15 明治製菓株式会社 Administration agent for occlusion of neovascularization of the fundus
US5756541A (en) * 1996-03-11 1998-05-26 Qlt Phototherapeutics Inc Vision through photodynamic therapy of the eye
NZ331977A (en) * 1996-03-26 2000-07-28 Pharmacyclics Inc Texaphyrin in photodynamic therapy of pigment-related lesions
US6043237A (en) * 1996-12-10 2000-03-28 Qlt Phototherapeutics, Inc. Use of photodynamic therapy for prevention of secondary cataracts
IL130246A0 (en) * 1996-12-11 2000-06-01 Pharmacyclics Inc Use of a texaphyrin in the preparation of a medicament for use in ocular diagnosis and therapy
US6270749B1 (en) 1996-12-11 2001-08-07 Pharmacyclics, Inc. Use of Texaphyrin in ocular diagnosis and therapy
US6022526A (en) * 1997-07-30 2000-02-08 Pharmacyclics, Inc. Use of texaphyrins in detection of melanin and melanin metabolites diagnostic of melanotic melanoma
US6117862A (en) * 1998-10-09 2000-09-12 Qlt, Inc. Model and method for angiogenesis inhibition
IL126953A0 (en) 1998-11-08 1999-09-22 Yeda Res & Dev Pharmaceutical compositions comprising porphyrins and some novel porphyrin derivatives
AU7106400A (en) * 1999-09-10 2001-04-10 Akorn, Inc. Fluorescent dye angiography and dye-enhanced photocoagulation
US6351663B1 (en) 1999-09-10 2002-02-26 Akorn, Inc. Methods for diagnosing and treating conditions associated with abnormal vasculature using fluorescent dye angiography and dye-enhanced photocoagulation
US6944493B2 (en) 1999-09-10 2005-09-13 Akora, Inc. Indocyanine green (ICG) compositions and related methods of use
US6443976B1 (en) 1999-11-30 2002-09-03 Akorn, Inc. Methods for treating conditions and illnesses associated with abnormal vasculature
EP1267935A2 (en) * 2000-01-12 2003-01-02 Light Sciences Corporation Novel treatment for eye disease
JP2003530146A (en) * 2000-02-10 2003-10-14 マサチューセッツ・アイ・アンド・イア・インファーマリー Photodynamic therapy to treat eye conditions
AU2006203034B2 (en) * 2000-02-10 2006-09-07 Massachusetts Eye And Ear Infirmary Methods and compositions for treating conditions of the eye
US7753943B2 (en) 2001-02-06 2010-07-13 Qlt Inc. Reduced fluence rate PDT
PT1357946E (en) 2001-02-06 2008-06-27 Quadra Logic Tech Inc Photodynamic therapy with reduced fluence rate
PL371929A1 (en) * 2001-11-09 2005-07-11 Eyetech Pharmaceuticals Methods for treating ocular neovascular diseases
US6723750B2 (en) 2002-03-15 2004-04-20 Allergan, Inc. Photodynamic therapy for pre-melanomas
AU2003299201A1 (en) 2002-10-03 2004-04-23 Light Sciences Corporation Excitation of photoreactive compounds in eye tissue

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5171749A (en) * 1987-01-20 1992-12-15 University Of British Columbia Wavelength-specific cytotoxic agents
US5214036A (en) * 1990-03-08 1993-05-25 University Of British Columbia Benzoporphyrin derivatives for photodynamic therapy

Also Published As

Publication number Publication date
CA2536069C (en) 2008-06-03
AU6813694A (en) 1995-10-03
WO1995024930A1 (en) 1995-09-21
CA2536069A1 (en) 1995-09-21
CA2185644C (en) 2011-04-12

Similar Documents

Publication Publication Date Title
CA2185644A1 (en) Use of green porphyrins in ocular diagnosis and therapy
CN1104908C (en) Improved vision through photodynamic therapy of eye
Richter et al. Liposomal delivery of a photosensitizer, benzoporphyrin derivative monoacid ring A (BPD), to tumor tissue in a mouse tumor model
Aizawa et al. Localization of mono‐L‐aspartyl chlorin e6 (NPe6) in mouse tissues
Blumenkranz et al. Lutetium texaphyrin (Lu-Tex): a potential new agent for ocular fundus angiography and photodynamic therapy
Jori Photosensitized processes in vivo: proposed phototherapeutic applications
Schmidt-Erfurth et al. Mechanisms of action of photodynamic therapy with verteporfin for the treatment of age-related macular degeneration
Spikes et al. Photodynamic therapy of tumours and other diseases using porphyrins
Reddi et al. Liposome-or LDL-administered Zn (II)-phthalocyanine as a photodynamic agent for tumours. I. Pharmacokinetic properties and phototherapeutic efficiency
US5484803A (en) Transcutaneous in vivo activation of photosensitive agents in blood
CA1339927C (en) Wavelength-specific cytotoxic agents
US5707986A (en) Angiographic method using green porphyrins in primate eyes
CA2437563A1 (en) Photodynamic therapy of occult age-related macular degeneration
AU657262B2 (en) Compositions containing green porphyrins to destroy malignant cells in mononuclear cell populations
Selman et al. Photodynamic treatment of transplantable bladder tumors in rodents after pretreatment with chloroaluminum tetrasulfophthalocyanine
US20040147501A1 (en) Photodynamic therapy
Gottfried et al. In vivo damage to chorioallantoic membrane blood vessels by porphycene-induced photodynamic therapy
van den Bergh Photodynamic therapy of age-related macular degeneration: History and principles
RU99117522A (en) PHOTOCHEMOTHERAPEUTIC COMPOSITIONS
Namatame et al. Photodynamic therapy of C6-implanted glioma cells in the rat brain employing second-generation photosensitizer talaporfin sodium
DE69722263T2 (en) USE OF TEXAPHYRINE IN THE PRODUCTION OF A MEDICINE FOR EYE THERAPY AND DIAGNOSIS
Evensen The use of porphyrins and non-ionizing radiation for treatment of cancer
Gottfried et al. Vascular damage during PDT as monitored in the chick chorioallantoic membrane
Delori et al. Excitation and emission spectra of fluorescein dye in the human ocular fundus.
Musser et al. Inability to elicit rapid cytocidal effects on L1210 cells derived from porphyrin-injected mice following in vitro photoirradiation

Legal Events

Date Code Title Description
EEER Examination request
MKEX Expiry

Effective date: 20140314